ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Autologous Anti-DLL3 CAR-T Cells DJI136

Also written as “DJI136” and “LB2102”.

In Novartis’s pipeline, DLL3 CAR-T. Its studies are mostly in Small Cell Lung Carcinoma · Carcinoma, Neuroendocrine, led by 2 companies.

Furthest: phase 2, since Dec 21, 20222 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Legend Biotech USAits history only11 open or runningphase 1since Dec 21, 2022Dec 21, 2022Dec 2027phase 1 · NCT05680922
Novartisits history only11 open or runningphase 2since Apr 27, 2026Apr 27, 2026Mar 3, 2031phase 2 · NCT07564401
  • Named in Novartis’s own pipeline as DJI136, phase 1, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2022First study: phase 1 study in Small Cell Lung Cancer Extensive StageNew to Legend Biotech USALegend Biotech USA · NCT05680922 · 41 enrolled · United States
  2. Apr 27, 2026Novartis’s first study: phase 2 study in Small Cell Lung CarcinomaNew to NovartisNovartis · NCT07564401 · 80 planned · United States, Australia, Singapore and more

Ahead

  1. Dec 2027Primary completion: phase 1 study in Small Cell Lung Cancer Extensive StageLegend Biotech USA · NCT05680922
  2. Mar 3, 2031Primary completion: phase 2 study in Small Cell Lung CarcinomaNovartis · NCT07564401

TargetBeta

“DLL3 CAR-T”the company's pipeline, read by Claude · source
“A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), ”NCIt, by rule

Other programs on DLL3

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
obrixtamigBoehringer Ingelheimphase 311
Zocilurtatug PelitecanruleZai Labphase 36
Anti-DLL3 Antibody-drug Conjugate BL-M14D1Sichuan Biokin Pharmaceuticalphase 34
gocatamigMerckphase 34
Anti-DLL3 Antibody-drug Conjugate IDE849ideaya-biosciencesphase 22
SHR-7787Jiangsu HengRui Medicinephase 21
Anti-DLL3 Antibody-drug Conjugate FZ-AD005ruleShanghai Fudan-Zhangjiang Bio-Pharmaceuticalphase 12
clesitamigHoffmann-La Rochephase 12
Actinium Ac 225-ABD147ruleabdera-therapeutics-incphase 11
Indium In 111-ETN029Novartisphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07564401Small Cell Lung Carcinoma · United States, Australia, Singapore and more2RecruitingNovartisMar 3, 203180
NCT05680922Small Cell Lung Cancer Extensive Stage · United States1Active, not recruitingLegend Biotech USADec 202741

How it is read

Names in the registry

  • “DJI136”, 1 entry
  • “LB2102”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.